Philadelphia Medical Weight Loss at W8MD
W8MD Weight Loss, Sleep & MedSpa provides comprehensive, physician-supervised medical weight loss in Philadelphia using modern GLP-1 injections and pills, traditional prescription medications, personalized nutrition, sleep-apnea care and long-term maintenance support.
- Semaglutide, tirzepatide, Wegovy and Zepbound evaluation
- Oral Wegovy tablets and Foundayo
- Phentermine, Qsymia, Contrave and other established options
- Insurance and affordable self-pay pathways
- Sleep medicine and home sleep testing
- More than 20 years of clinical experience
Why Physician-Supervised Weight Loss Is Different
Weight gain is rarely caused by willpower alone. Appetite biology, insulin resistance, menopause, PCOS, medications, stress, emotional eating, sleep deprivation, obstructive sleep apnea, genetics and repeated dieting can all influence weight.
W8MD evaluates these factors and helps patients choose a treatment they can use safely, afford realistically and continue long enough to support meaningful health improvement.
- Medical, surgical, medication and family-history review
- Assessment of appetite, cravings, food noise and eating patterns
- Screening for contraindications and drug interactions
- Review of weight-related conditions and sleep symptoms
- Discussion of injection, tablet and nonmedication choices
- Insurance, pharmacy access and total-cost planning
- Follow-up for side effects, plateaus and maintenance
Philadelphia Weight Loss Services Available at W8MD
Treatment is personalized. Not every patient requires medication, and not every medication or service is appropriate for every patient.
Medical Weight Loss Consultation
Review of medical history, current medications, weight pattern, previous treatment, eating habits, sleep and goals.
GLP-1 and Incretin Treatment
Evaluation for semaglutide, tirzepatide, Wegovy, Zepbound, oral Wegovy tablets, Foundayo, Saxenda or another appropriate option.
Affordable Philadelphia GLP-1 information →Traditional Prescription Medications
Selected patients may be considered for phentermine, Qsymia, Contrave, diethylpropion, phendimetrazine, orlistat or other medically appropriate treatment.
Personalized Nutrition
Lower-carbohydrate, low-glycemic, reduced-calorie and protein-focused plans can be adjusted for medications, culture, schedule, metabolic health and food preferences.
Explore the W8MD weight loss diet →Meal Replacements and Low-Calorie Plans
Selected patients may use protein shakes, portion-controlled meals, low-calorie diets or medically supervised very-low-calorie plans.
Sleep Apnea and Sleep Medicine
W8MD can screen for obstructive sleep apnea, arrange home sleep testing for eligible patients and coordinate treatment with the weight-loss plan.
Explore W8MD sleep medicine →Ongoing Monitoring
Follow-up may address appetite, side effects, dose changes, protein intake, hydration, constipation, plateaus and insurance problems.
Long-Term Weight Maintenance
Medication reassessment, nutrition transitions, relapse prevention and early intervention for weight regain are built into long-term care.
Learn about GLP-1 maintenance →In-Person and Eligible Telehealth Care
Telehealth may be available when permitted by the patient’s physical location, clinician licensure, clinical needs and prescribing requirements.
Weight Loss Medications Available for Evaluation
The best medication depends on medical history, side-effect risks, personal preference, insurance, pharmacy availability and sustainable cost—not simply which drug is newest.
Wegovy — Semaglutide
Wegovy is FDA-approved to reduce excess body weight and support long-term weight maintenance in eligible patients. Injectable Wegovy is also approved for selected cardiovascular-risk and MASH indications.
- Standard once-weekly dosing
- Newer 7.2 mg adult option for selected patients
- Approved for obesity in selected adolescents age 12 and older
- Requires gradual dose escalation and monitoring
Zepbound — Tirzepatide
Zepbound is FDA-approved for chronic weight management in eligible adults. It is also approved for moderate-to-severe obstructive sleep apnea in selected adults with obesity.
- Once-weekly injection
- Gradual dose escalation
- Insurance commonly requires prior authorization
- Important gastrointestinal, gallbladder and pregnancy precautions
Wegovy Tablets
Wegovy tablets contain semaglutide and provide an FDA-approved daily oral weight-management option for eligible adults.
- Daily tablet with gradual escalation
- Specific empty-stomach and water instructions
- Waiting period before food, beverages or other oral medicines
- Not the same product or indication as diabetes-dose Rybelsus
Foundayo — Orforglipron
Foundayo is a once-daily oral, nonpeptide GLP-1 receptor agonist approved in 2026 for eligible adults with obesity or overweight plus a qualifying weight-related condition.
- Can be taken with or without food
- Requires gradual dose escalation
- Drug-interaction and contraceptive considerations
- Should not be combined with another GLP-1 receptor agonist
Saxenda — Liraglutide
Saxenda remains an FDA-approved daily injectable treatment for selected adults and adolescents. It may be considered when daily dosing, a shorter-acting GLP-1 or insurance coverage makes it a reasonable option.
Qsymia — Phentermine and Topiramate ER
Qsymia combines phentermine with extended-release topiramate. Pregnancy prevention and monitoring are especially important because of fetal risk.
Contrave — Naltrexone and Bupropion
Contrave may help selected patients with appetite and cravings. It is not appropriate with opioid use and requires review of seizure risk, blood pressure, psychiatric history and interactions.
Xenical and Alli — Orlistat
Orlistat reduces absorption of dietary fat. It does not directly suppress appetite and may cause gastrointestinal effects and require attention to fat-soluble vitamins and drug interactions.
Phentermine, Diethylpropion and Phendimetrazine
These stimulant-related medicines may be useful for selected patients but require cardiovascular, blood-pressure, anxiety, insomnia, glaucoma, pregnancy and controlled-substance review.
Imcivree — Setmelanotide
Imcivree is intended for selected rare, genetically confirmed obesity disorders. It is not a general treatment for common obesity.
Additional Philadelphia Medical Weight Loss Options
Medication can be helpful, but it works best as part of a plan that also addresses nutrition, sleep, movement, side effects and maintenance.
Lower-Carbohydrate Nutrition
Reduced refined carbohydrates and lower-glycemic meals may help selected patients manage hunger, blood sugar and insulin resistance.
Lean-Mass Protection
Protein goals and resistance activity may help reduce loss of lean tissue during significant weight reduction.
Meal Replacements
Protein shakes and portion-controlled meals may simplify calorie control for selected patients who prefer structure and convenience.
Medically Supervised Low-Calorie Diets
Some patients may qualify for carefully monitored low-calorie or very-low-calorie plans. These are not appropriate for everyone and should not be attempted without clinical supervision.
Cravings and Eating Patterns
Follow-up can address emotional eating, late-night eating, restaurant habits, food noise, travel and high-risk situations.
Maintenance and Regain Prevention
W8MD helps patients plan for changing appetite, medication adjustments, goal-weight transitions and early signs of regain.
Learn about weight regain after GLP-1 therapy →How Common Weight Loss Options Differ
| Option | How taken | Potential advantage | Important considerations |
|---|---|---|---|
| Wegovy | Weekly injection or daily tablet | Strong modern GLP-1 option with multiple FDA indications | Gastrointestinal effects, gallbladder and pancreatitis precautions, pregnancy, thyroid-related contraindications and tablet timing |
| Zepbound | Weekly injection | Dual GIP/GLP-1 treatment; also approved for selected adults with obesity-related OSA | Gastrointestinal effects, pregnancy, gallbladder and pancreatitis precautions, thyroid-related contraindications and oral contraceptive considerations |
| Foundayo | Daily tablet | Needle-free oral GLP-1 option that can be taken with or without food | Drug interactions, gastrointestinal effects, pregnancy, thyroid-related contraindications and contraceptive considerations |
| Qsymia | Daily capsule | Long-term oral option that may be less costly than brand GLP-1 therapy | Pregnancy risk, mood or cognitive effects, heart rate, glaucoma, hyperthyroidism and gradual discontinuation |
| Contrave | Daily tablets with escalation | May help selected patients with appetite and cravings | Opioid use, seizure risk, uncontrolled hypertension, eating disorders and psychiatric or drug-interaction review |
| Phentermine | Daily tablet or capsule | Established, generally lower-cost appetite suppressant | Short-term indication, controlled-substance status, heart rate, blood pressure, insomnia, anxiety and pregnancy |
| Orlistat | With fat-containing meals | Nonstimulant and non-GLP-1 approach | Gastrointestinal effects, vitamin absorption and medication interactions |
| Nutrition-only plan | Daily eating and activity plan | No prescription medication exposure | Requires sustained adherence; may be insufficient alone for some patients with severe obesity or strong biological hunger |
Affordable Philadelphia GLP-1 Starting Prices
W8MD accepts many insurance plans for qualifying medical visits and offers self-pay alternatives. Visit coverage and medication coverage are separate.
Semaglutide-Based Programs
$29.99+Published weekly starting-dose pricing for certain eligible patients using insurance for the qualifying medical visit.
Published self-pay programs begin at $59.99+ per week.
Tirzepatide-Based Programs
$45.00+Published weekly starting-dose pricing for certain eligible patients using insurance for the qualifying medical visit.
Published self-pay programs begin at $69.99+ per week.
Starting prices apply only to qualifying programs and starting doses and may refer to compounded prescription medication when legally available and clinically appropriate. Compounded drugs are not FDA-approved and are not the same as Wegovy or Zepbound. Total cost varies by dose, medication source, pharmacy, shipping, laboratory needs, visit coverage, copay, deductible, coinsurance and other program charges. Brand-name medication pricing is separate and often depends on pharmacy benefits and prior authorization. Prices and availability may change.
How W8MD Helps Choose the Best Option for You
Two patients with the same body mass index may need very different plans. W8MD physicians compare potential benefit, safety, convenience, insurance and total cost before recommending treatment.
- Medical history: cardiovascular disease, diabetes, gallbladder disease, pancreatitis, kidney or liver problems, thyroid-cancer history, seizures, glaucoma and other conditions.
- Current medications: insulin, diabetes drugs, opioids, antidepressants, stimulants, seizure medicines and oral contraceptives.
- Preference: weekly injection, daily tablet, stimulant, nonstimulant or medication-free approach.
- Insurance: formulary, prior authorization, step therapy, deductible, copay and pharmacy benefit.
- Cost: dose-related medication price, visits, laboratory testing, shipping and expected duration.
- Long-term fit: adherence, side-effect tolerance, maintenance needs and risk of weight regain.
Weight Loss and Sleep Apnea Care in One Program
Poor sleep and obstructive sleep apnea may worsen fatigue, appetite regulation, blood pressure and metabolic health. W8MD can address these connected problems rather than treating weight in isolation.
- Screening for snoring and witnessed breathing pauses
- Evaluation of daytime sleepiness and morning headaches
- Convenient home sleep testing for appropriate patients
- Professional interpretation and treatment recommendations
- CPAP, APAP or BPAP support when indicated
- Zepbound evaluation for eligible adults with obesity-related OSA
Weight loss may improve obstructive sleep apnea, but patients should not stop prescribed PAP or another therapy without medical guidance.
Your W8MD Philadelphia Weight Loss Journey
Request an Appointment
Call 215-676-2334 or use the W8MD appointment page.
Complete Medical Review
Discuss health history, weight pattern, medications, symptoms and previous treatment.
Compare Options
Review GLP-1 injections, pills, traditional medications, nutrition, insurance and costs.
Begin a Personalized Plan
Start the chosen medication, nutrition or combination plan when clinically appropriate.
Monitor Safety and Progress
Review appetite, side effects, weight, blood pressure, adherence and sleep symptoms.
Plan for Maintenance
Address plateaus, goal-weight transition, medication reassessment and prevention of regain.
W8MD Weight Loss Results and Testimonials
These stories show individual experiences. Results vary and no particular amount of weight loss or health improvement is guaranteed.
D.M. described the program as “truly a life changer,” reported losing 87 pounds in ten months and later reaching approximately 100 pounds lost with long-term maintenance.D.M. — Published W8MD patient story
Dawn V. reported losing approximately 150 pounds and emphasized medical guidance, accountability and ongoing encouragement from the physician and staff.Dawn V. — Published W8MD patient story
Tom G. reported losing 75 pounds over nine months, increased energy and improved ability to walk and climb stairs while receiving weight and sleep care.Tom G. — Published Philadelphia patient story
Emerging Weight Loss Medications
These treatments remain investigational for routine obesity care as of July 2026. They should not be represented as FDA-approved or sold as “research use only” products for self-treatment.
Retatrutide
An investigational weekly medicine targeting GIP, GLP-1 and glucagon receptors in phase 3 obesity studies.
View a retatrutide trial →CagriSema
An investigational combination of semaglutide and the amylin analogue cagrilintide.
View a CagriSema trial →Survodutide
An investigational glucagon and GLP-1 receptor agonist being studied for obesity and metabolic liver disease.
View a survodutide trial →MariTide
Maridebart cafraglutide is an investigational long-acting GIP-receptor antibody and GLP-1 receptor agonist.
VK2735
An investigational dual GIP and GLP-1 receptor agonist being studied in injectable and oral forms.
Eloralintide and Other Amylin Therapies
Investigational amylin-based treatments are being studied alone and in combination with incretin medicines.
Philadelphia Medical Weight Loss Location and Service Area
The active W8MD Pennsylvania office is located in Northeast Philadelphia. The older King of Prussia and Cherry Hill references on the previous page should be removed.
Northeast Philadelphia
Bustleton, Somerton, Rhawnhurst, Fox Chase, Torresdale and nearby city neighborhoods.
Bucks County
Bensalem, Feasterville-Trevose, Southampton, Langhorne and nearby communities.
Montgomery County
Huntingdon Valley, Abington, Willow Grove, Jenkintown and surrounding areas.
South Jersey and Delaware
Patients from Cherry Hill, Marlton, Voorhees, Camden County and Delaware who find the Philadelphia office convenient.
W8MD Weight Loss, Sleep & MedSpa — Philadelphia
1718 Welsh Road2nd Floor, Suite C
Philadelphia, PA 19115 215-676-2334
Philadelphia Weight Loss Resources
Philadelphia Medical Weight Loss FAQ
What is medical weight loss?
Medical weight loss is a physician-supervised approach that may include medical evaluation, nutrition, physical activity, behavioral strategies, prescription medication, sleep-apnea care and long-term maintenance. It is not the same as a commercial diet or medication-only service.
What GLP-1 medications does W8MD Philadelphia evaluate?
Eligible patients may discuss Wegovy, semaglutide-based treatment, Zepbound, tirzepatide-based treatment, oral Wegovy tablets, Foundayo, Saxenda or another medically appropriate option. Availability, diagnosis, pharmacy source, insurance and cost vary.
Does W8MD prescribe phentermine and traditional diet pills?
Selected patients may be evaluated for phentermine, Qsymia, Contrave, diethylpropion, phendimetrazine, orlistat or another appropriate option. Medical history, blood pressure, pregnancy, controlled-substance considerations and drug interactions must be reviewed. A consultation does not guarantee a prescription.
How much do semaglutide and tirzepatide cost?
Published starting-dose pricing begins at $29.99 per week for semaglutide-based programs and $45 per week for tirzepatide-based programs for certain eligible patients using insurance for the medical visit. Published self-pay starting prices are $59.99 and $69.99 per week, respectively. Total cost varies and prices may change.
Does W8MD accept insurance in Philadelphia?
W8MD accepts many insurance plans for qualifying medical visits. Participation varies by provider and plan. Medication coverage is separate from visit coverage, and copays, deductibles, coinsurance, formularies and prior authorization may apply.
Can W8MD help with Wegovy or Zepbound prior authorization?
W8MD may help eligible patients submit documentation when their insurance plan includes weight-loss medication coverage. The insurer determines approval, formulary requirements and out-of-pocket cost.
Who may qualify for an FDA-approved weight loss medication?
Eligibility depends on the product, body mass index, weight-related medical conditions, age, previous treatment, contraindications, pregnancy status and other clinical factors. A clinician must make an individualized determination.
Does W8MD help patients maintain weight loss?
Yes. W8MD emphasizes follow-up, medication reassessment, protein and nutrition planning, sleep care, plateau management and early intervention for regain. No program can guarantee permanent weight loss.
Does W8MD provide home sleep studies?
Eligible patients with suspected uncomplicated obstructive sleep apnea may qualify for a convenient home sleep study. A clinician determines whether home or attended testing is appropriate.
Is retatrutide available at W8MD?
Retatrutide remains investigational for routine obesity treatment as of July 2026. W8MD can provide education about emerging medicines but should not sell or prescribe an unapproved product outside an authorized clinical trial.
Are telehealth appointments available?
Telehealth may be available when clinically appropriate and permitted by the patient’s physical location, clinician licensure, medical needs and applicable prescribing rules. Some treatments require an in-person examination.
FDA Resources
Start a Personalized Philadelphia Medical Weight Loss Plan
Meet with W8MD to compare GLP-1 injections, oral weight-loss medicines, traditional prescription options, nutrition, sleep-apnea evaluation, insurance coverage, self-pay choices and long-term maintenance.